BMRN vs VXRT · P/E 40, rev $2.85B vs rev $28.7M
Biomarin Pharmaceutical Inc (BMRN) versus Vaxart Inc (VXRT) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Vaxart Inc (VXRT) is a biotechnology company listed on US.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported VXRT revenue for 2024-12-31 was $28.7M. Net income was -$66.9M. Revenue was up 288.9% from 2023-12-31 to 2024-12-31. VXRT currently screens at market cap $73.0M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. VXRT currently screens at market cap $73.0M.
Not investment advice. Open the BMRN and VXRT stock pages for the full models.
Not investment advice.